KemPharm, the Nasdaq-listed specialty pharmaceutical company, has appointed Nichol Ochsner as vice president of IR and corporate communications.
Ochsner has worked for a string of healthcare companies in senior IR roles. Most recently, she served as executive vice president of IR and corporate communications at Statera Biopharma.
Prior to that, she held similar roles at TherapeuticsMD, Aralez Pharmaceutical and Auxilum Pharmaceuticals, which was acquired by Endo International for roughly $2.6 bn in 2014.
Other roles have been at companies including Medarex, Kos Pharmaceuticals, Genta and Enzon Pharmaceuticals.
Two decades of experience
‘We are very pleased to welcome Nichol to KemPharm and look forward to benefiting from her more than 20 years’ experience developing investor relations and corporate communications strategies in the biopharmaceutical industry,’ said Travis Mickle, president and CEO of KemPharm, in a statement.
‘Nichol possesses an extensive communications skillset that is ideally suited to positioning such a multifaceted value proposition and conveying our unique vision to the investment community and other constituents.’
Ochsner adds: ‘I am very excited to join KemPharm at this important time in the company’s growth and evolution.
‘KemPharm is rare among small biopharmaceutical companies in that it possesses a deep and diverse clinical pipeline coupled with revenue-generating pre-NDA and commercial-stage assets, along with a strong balance sheet.’
